Have a feature idea you'd love to see implemented?
Let us know!
RGNX REGENXBIO Inc
Price (delayed)
$9.18
Market cap
$454.82M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5.02
Enterprise value
$480.24M
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform,
Highlights
RGNX's EPS is up by 16% year-on-year and by 4.6% since the previous quarter
The net income is up by 8% YoY
The quick ratio has declined by 15% since the previous quarter but it has increased by 4.6% year-on-year
RGNX's gross profit is down by 24% year-on-year and by 9% since the previous quarter
The equity has contracted by 17% YoY and by 13% from the previous quarter
Key stats
What are the main financial stats of RGNX
Market
Valuations
Earnings
Shares outstanding
49.55M
Market cap
$454.82M
Enterprise value
$480.24M
Price to book (P/B)
1.51
Price to sales (P/S)
5.53
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.69
Revenue
$84.33M
EBIT
-$234.35M
EBITDA
-$217.83M
Free cash flow
-$184.74M
Per share
Balance sheet
Liquidity
EPS
-$5.02
Free cash flow per share
-$3.64
Book value per share
$6.1
Revenue per share
$1.66
TBVPS
$10.22
Total assets
$519.11M
Total liabilities
$217.7M
Debt
$84.06M
Equity
$301.42M
Working capital
$210.67M
Debt to equity
0.28
Current ratio
3.05
Quick ratio
2.74
Net debt/EBITDA
-0.12
Margins
Efficiency
Dividend
EBITDA margin
-258.3%
Gross margin
54.4%
Net margin
-283.2%
Operating margin
-291.6%
Return on assets
-41.7%
Return on equity
-70.6%
Return on invested capital
-48.7%
Return on capital employed
-56.3%
Return on sales
-277.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RGNX stock price
How has the REGENXBIO stock price performed over time
Intraday
-4.67%
1 week
-17.59%
1 month
-11.48%
1 year
-53.87%
YTD
-48.86%
QTD
-12.49%
Financial performance
How have REGENXBIO's revenue and profit performed over time
Revenue
$84.33M
Gross profit
$45.84M
Operating income
-$245.88M
Net income
-$238.81M
Gross margin
54.4%
Net margin
-283.2%
RGNX's gross profit is down by 24% year-on-year and by 9% since the previous quarter
The company's revenue fell by 15% YoY and by 5% QoQ
The gross margin has declined by 11% year-on-year and by 4.2% since the previous quarter
RGNX's operating margin is down by 11% year-on-year and by 4.4% since the previous quarter
Growth
What is REGENXBIO's growth rate over time
Valuation
What is REGENXBIO stock price valuation
P/E
N/A
P/B
1.51
P/S
5.53
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.69
RGNX's EPS is up by 16% year-on-year and by 4.6% since the previous quarter
RGNX's P/B is 40% below its 5-year quarterly average of 2.5 and 28% below its last 4 quarters average of 2.1
The equity has contracted by 17% YoY and by 13% from the previous quarter
The price to sales (P/S) is 50% lower than the 5-year quarterly average of 11.0 and 33% lower than the last 4 quarters average of 8.2
The company's revenue fell by 15% YoY and by 5% QoQ
Efficiency
How efficient is REGENXBIO business performance
The ROIC has contracted by 21% YoY and by 4.7% from the previous quarter
The ROE is down by 19% YoY and by 3.5% QoQ
REGENXBIO's ROA has decreased by 16% YoY and by 4% from the previous quarter
RGNX's return on sales is down by 10% year-on-year and by 4.9% since the previous quarter
Dividends
What is RGNX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RGNX.
Financial health
How did REGENXBIO financials performed over time
RGNX's total assets is 138% greater than its total liabilities
RGNX's total liabilities is down by 20% year-on-year
RGNX's total assets is down by 18% year-on-year and by 9% since the previous quarter
REGENXBIO's debt is 72% lower than its equity
The equity has contracted by 17% YoY and by 13% from the previous quarter
RGNX's debt to equity is up by 12% since the previous quarter and by 12% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.